Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AveXis licenses REGENXBIO's NAV AAV9 vector for rare CNS diseases

Executive Summary

In a new deal that builds on their 2014 agreement, AveXis Inc. licensed exclusive worldwide rights to REGENXBIO Inc.'s adeno-associated virus vector NAV AAV9 to develop and commercialize gene therapies for the rare neurological disorders Rett syndrome (RTT; caused by an X-linked dominant mutation in the methyl CpG binding protein 2 (MECP2) gene) and amyotrophic lateral sclerosis (ALS; caused by mutations in the superoxide dismutase 1 (SOD1) gene).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies